Assoc. Prof. Dr. MD Halil GENÇ

1. Genc H, Dogru T, Tapan S et al. Soluble CD40 ligand, soluble P-selectin and von Willebrand factor levels in subjects with prediabetes: The impact of metabolic syndrome. Clin Biochem. 2012 Jan;45(1-2):92-5.

2. Genc H, Dogru T, Tapan S et al. Circulating vaspin and its relationship with insulin sensitivity, adiponectin, and liver histology in subjects with non-alcoholic steatohepatitis. Scand J Gastroenterol. 2011;46(11):1355-61.

3. Sonmez A, Haymana C, Tapan S, Safer U, Celebi G, Ozturk O, Genc H, et al. Chitotriosidase activity predicts endothelial dysfunction in type-2 diabetes mellitus. Endocrine. 2010;37(3):455-9.

4. Kilciler G, Genc H, Tapan S, et al. Mean platelet volume and its relationship with carotid atherosclerosis in subjects with non-alcoholic fatty liver disease. Ups J Med Sci. 2010;115(4):253-9.

5. Tapan S, Dogru T, Kara M, Ercin CN, Kilciler G, Genc H, et al. Circulating levels of interleukin-18 in patients with non-alcoholic fatty liver disease. Scand J Clin Lab Invest. 2010;70(6):399-403.

6. Sonmez A, Celebi G, Erdem G, Tapan S, Genc H et al. Plasma apelin and ADMA Levels in patients with essential hypertension. Clin Exp Hypertens. 2010;32(3):179-83.

7. Tasci I, Erdem G, Ozgur G, Tapan S, Dogru T, Genc H, et al. LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia. Atherosclerosis. 2009;204(1):222-

8. Erdem G, Genç H, Tapan S, et al. Circulating von Willebrand factor levels in patients with prediabetes. Turkish J Med Sci 2008;28(6):822-27.

9. Dogru T, Genc H, Tasci I, et al. Platelet aggregation is not enhanced in patients with prediabetes. Ups J Med Sci. 2007;112(3):338-46.

10. Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract. 2007;76(1):24-9.

11. Tasci I, Dogru T, Sonmez A, Genc H et al. Soluble CD40 ligand levels in otherwise healthy subjects with impaired fasting glucose. Mediators Inflamm. 2006;2006(5):32508.

12. Dogru T, Tasci I, Sonmez A, Genc H, et al. The plasma levels of soluble P-selectin in subjects with prediabetes. Int J Clin Pract. 2006;60(9):1048-52.

13. Dogru T, Genc H, Tapan S. Hyperuricemia in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;34(8):1042-3

14. Dogru T, Genc H, Ercin CN, Tapan S. Non-invasive prediction of fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2011;55(2):498-9.

15. Dogru T, Genc H, Kara M, Karadurmus N. Microalbuminuria and nonalcoholic fatty liver disease. Metabolism. 2010;59(9):E5

16. Dogru T, Karadurmus N, Tapan S, Genc H. Comment and reply on: Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2010;45(7-8):1000-1.

17. Genc H, Karadurmus N, Kisa U et al. T. Transforming growth factor β (TGF-β) levels in otherwise healthy subjects with impaired glucose tolerance. Endokrynol Pol. 2010;61(6):691-4.

18. Dogru T, Sonmez A, Tasci I, Genc H. Symptomatic hypocalcemia due to oral risedronate therapy. Ind. J. Med. Sci 2005;59:542-543

19. Sonmez A, Nikolic D, Dogru T, Ercin CN, Genc H, Cesur M, Tapan S, Karslioglu Y, Montalto G, Banach M, Toth P, Rizzo M. Low- and high-density lipoprotein subclasses in subjects with non-alcoholic fatty liver disease. J Clin Lipidol. 2015 Jul-Aug;9(4):576-582.

20. Celebi G, Genc H, Gurel H, et al. The relationship of circulating fetuin-a with liver histology and biomarkers of systemic inflammation in nondiabetic subjects with nonalcoholic fatty liver disease. Saudi J Gastroenterol. 2015 May-Jun;21(3):139-45.

21. Sertoglu E, Ercin CN, Celebi G, Gurel H, Kayadibi H, Genc H, et al. The relationship of serum uric acid with non-alcoholic fatty liver disease. Clin Biochem. 2014

22. Kara M, Genc H, Tapan S, et al. Alpha fetoprotein levels and its relationship with histopathological findings in patients with non-alcoholic fatty liver disease. Eur Rev Med Pharmacol Sci. 2013 Jun;17(11):1536-41.

23. Gurel H, Genc H, Celebi G et al. Plasma pentraxin-3 is associated with endothelial dysfunction in non-alcoholic fatty liver disease. Eur Rev Med Pharmacol Sci. 2016 Oct;20(20):4305-4312.

1. Dogru T, Genc H, Ercin CN. Carotid atherosclerosis or nonalcoholic fatty liver disease: which comes first? Atherosclerosis. 2013 Dec;231(2):187-8.

2. Dogru T, Genc H,. C reactive protein levels in non-alcoholic fatty liver disease. J Hepatol. 2012 Feb;56(2):507-8

3. Dogru T, Genc H, Tapan S, Hyperuricemia in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;34(8):1042-3

4. Dogru T, Genc H, Ercin CN, Tapan S. Non-invasive prediction of fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2011;55(2):498-9.

5. Dogru T, Genc H, Kara M, Karadurmus N. Microalbuminuria and nonalcoholic fatty liver disease. Metabolism. 2010;59(9):5

6. Dogru T, Karadurmus N, Tapan S, Genc H. Comment and reply on: Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2010;45(7-8):1000-1.

1. Genc H, Dogru T, Celebi G et al. Non-alcoholic fatty liver disease per se is not associated with carotid atherosclerosis.Gulhane Medical Journal, 2013; 55(2):84-88.

2. Kara M, Genc H. Comparison of the asymmetric dimethyl arginine levels and carotid intima media thickness with hemoglobin levels in patients with non-alcholic fatty liver disease Gulhane Medical Journal, 2012; 54(1):40-48.

1. Tapan S, Dogru T, Tasci I, Sonmez A, Erdem G, Genc H, et al. Decreased plasma apelin is positively correlated with adiponectin in patients with treatment naive type 2 DM. 15th Meeting of Balkan Clinical Laboratory Federation, Balkan Journal of Clinical Laboratory 2007;XIV,07,1:Abs.OP-14.

2. Cintosun U, Dogru T, H Genc, et al. TWEAK; a novel player in the pathogenesis of hepatic fibrosis in non alcoholic fatty liver disease? 24th Conference of the Asian Pacific Association for the Study of the Liver (APASL), Istanbul. Hepatol Int (2015) 9 (Suppl 1): S365.

3. Ercin CN, Dogru T, Genc H, et al. A. Insulin resistance but not visceral adiposity index is associated with liver fibrosis in nondiabetic subjects with nonalcoholic fatty liver disease. 24th Conference of the Asian Pacific Association for the Study of the Liver (APASL), Istanbul. Hepatol Int (2015) 9 (Suppl 1): S369.

4. Genc H, Dogru T, Celebi G, et al. High plasma levels of pentraxin 3 is associated with endothelial dysfunction in non alcoholic fatty liver disease. 24th Conference of the Asian Pacific Association for the Study of the Liver (APASL), Istanbul. Hepatol Int (2015) 9 (Suppl 1): S376.

5. Hancerliogullari O, Meral UM, Genc H. Hyperbilirubinemia after Surgery: Postoperative Diagnosed Gilbert’s Disease.The 49th Congress of the European Society for Surgical Research May 21-24, 2014, Budapest, Hungary Eur Surg Res 2014;52:93-250.

6. Sonmez A, Celebi G, Erdem G, Tapan S, Genc H, et al. Plasma apelin and ADMA levels in patients with essential hypertension. 20th European Meeting on Hypertension Oslo, Norway, 18-21 June 2010. Journal of Hypertension, Vol:28, e-Supplement A, June 2010, PP.12.451

7. Koc B., Sonmez A., Dogru T., Tasci I., Genc H., et al. Leptin levels in young, non-obese, male smokers and non-smokers. Atherosclerosis Supplements, XIV. International Symposium on Atherosclerosis, Rome, vol. 7, 417, Tu-P13:323, Elsevier, Ireland, 2006.

8. Dogru, T., Sonmez, A., Genc H et al. The effect of fibrinogen and platelet aggregation on cardiovascular risk in prediabetic subjects, Atherosclerosis Supplements, XIV. International Symposium on Atherosclerosis, Rome, vol. 7, 395, Tu-P11:226, Elsevier, Ireland, 2006.

9. Dogru, T., Tasci, I., Sonmez, A., Genc, H., et al. “Soluble P-selectin levels in subjects with prediabetes”, Atherosclerosis Supplements, XIV. International Symposium on Atherosclerosis, Rome, vol. 7, 206, Tu-P7:96, Elsevier, Ireland, 2006.

10. I Tasci, T. Dogru, A.Sonmez, H. Genc, et al. Soluble CD40 Ligand levels in otherwise healthy subjects with impaired fasting glucose. 2nd International Congress on Prediabetes and The Metabolic Syndrome, Barcelona, Diabetes & Vascular Disease Research, 2007:4(Supplement 1); S106 a

11. Ercin CN, Dogru T, Genc H, et al. Insulin Resistance But Not Visceral Adiposity Index Is Associated With Liver Fibrosis In Nondiabetic Subjects With Nonalcoholic Fatty Liver Disease. 14th International Euroasian Congress of Gastroenterology and Surgery. Euroasian Journal of Hepato-Gastroenterology. 2014 July-December volume 3 issue 2

12. Genc H, Meral UM, Hancerlioglu O, Alper E.Esophageal obstruction after mixture of grain meal. 14th International Euroasian Congress of Gastroenterology and Surgery. Euroasian Journal of Hepato-Gastroenterology. 2014 July-December volume 3 issue 2

13. Haymana C, Sonmez A, Tapan S, Safer U, Celebi G, Ozturk O, Genc H et al. Chitotriosidase activity predicts endothelial dysfunction in type-2 diabetes mellitus. 12th Europan Congress of Endocrinology 24-28 April, Prague, Czech Republic

14. S. Tapan ,A Sonmez , T Dogru , H.Genc, et al. ISKEMIA-MODIFIED ALBUMIN CAN BE A MARKER FOR DIABETES MELLITUS BUT NOT FOR IMPAIRED GLUKOSE TOLERANCE. The 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy), May 13-16. 2010

15. Sonmez A, Genc H, Celebi G, et al. The relationship between the hemoglobin levels and the cardiovascular risk factors in prediabetes. 3rd International Congress on Prediabetes and the Metabolic Syndrome, Nice, France, A140, 1-4 April 2009.

16. Erdem G, Genc H, Tapan S, et al. The leukocyte and platelet indices in patients with impaired glucose tolerance, The 2nd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy), Spain, s36A, 30 October-2 November 2008.

17. Erdem G, Genc H, Tapan S, et al. Circulating von Willebrand factor levels in patients with prediabetes. The 2nd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy), Spain, 30 October-2 November 2008, s35A.

1. Sönmez A, Genç H, Çelebi G, et al. Is there a relationship between hemoglobin levels and cardiovascular risk factors in cases of prediabetes? 45th National Diabetes Congress, May 20-24, 2009, Antalya, Turkey. Program and Summary Book, SS06, 2009.

2. Taşcı İ, Erdem G, Özgür G, Tapan S, Dogru T, Genç H, et al. In cases with isolated hypercholesterolemia, lowering LDL cholesterol increases plasma apelin levels. 10th National Internal Medicine Congress, Antalya, 2008:S10.

3. Aslan F, Genc H, Celebi G, et al. What would you do if a patient who has undergone endoscopic band ligation due to esophageal variceal bleeding experiences a heart attack? P189. 28th National Gastroenterology Week, November 16-20, 2011, Antalya

4. Genc H, Dogru T, Ercin CN, et al. The white blood cell count in circulating blood is increasing in non-alcoholic fatty liver disease. P174. 28th National Gastroenterology Week, November 16-20, 2011, Antalya.

5. Genc H, Dogru T, Ercin CN, et al. The relationship of uric acid levels with histopathological findings in non-alcoholic fatty liver disease. P171. 28th National Gastroenterology Week, November 16-20, 2011, Antalya.

6. Dogru T, Genc H, Tapan S, et al. The role of fetuin-a in the increased cardiovascular risk in non-alcoholic fatty liver disease. P169. 28th National Gastroenterology Week, November 16-20, 2011, Antalya

7. Aslan F, Genc H, Sakin YS, et al. Dermatomyositis and Crohn’s disease association: case presentation. P112. 28th National Gastroenterology Week, November 16-20, 2011, Antalya

8. Sakin YS, Polat Z, Yildiz B, Genc H, et al. A patient with ACUTE HEPATITIS A,B AND D COINFECTION WHO PRESENTS WITH ACUTE CHOLESTASIS: CASE PRESENTATION P163. 28th National Gastroenterology Week, November 16-20, 2011, Antalya.

9. Sakin YS, Polat Z, Aslan F, Tüzün A, Genç H, et al. CORROSIVE ESOPHAGITIS-DUODENITIS AND PYLORIC STENOSIS. ENDOSCOPIC TREATMENT OR SURGICAL TREATMENT? P30 28th National Gastroenterology Week, November 16-20, 2011, Antalya.

10. Polat Z, Küçükyıldırım S, Erdem B, Uygun A, Kantarcıoğlu M, Genç H et al. CK20 and MUC1 mRNA in the peripheral blood of gastrointestinal cancer patients. P333. 28th National Gastroenterology Week, November 16-20, 2011, Antalya.

11. Polat Z, Küçükyıldırım S, Kantarcıoğlu M, Erdem B, Gülşen M, Kilciler G, Çelebi G, Ergün H, Genç H, et al. Evaluation of the total RNA amount in peripheral blood as a metastatic marker in patients with colorectal cancer P331 28th National Gastroenterology Week, November 16-20, 2011, Antalya

12. Aslan F, Çelebi G, Sakin YS, Genç H et al. A RARE CAUSE OF UPPER GASTROINTESTINAL BLEEDING; CASE PRESENTATION OF ISCHEMIC ESOPHAGITIS. P2 28th National Gastroenterology Week, November 16-20, 2011, Antalya.

13. Aslan F, Çelebi G, Polat Z, Kantarcıoğlu M, Genç H et al. ILEOCECAL VALVE PERFORATION ANOMALY; Case Presentation P285. 28th National Gastroenterology Week, November 16-20, 2011, Antalya

14. Karadurmus N, Dogru T, Genc H, et al. The approach of doctors applying immunosuppressive treatment to screening for hepatitis B infection. P 91. 27th National Gastroenterology Week 24-28 November 2010, Antalya.

15. Genc H, Dogru T, Tapan S, et al. Investigation of glucose tolerance abnormalities in non-alcoholic fatty liver disease. P274. 27th National Gastroenterology Week 24-28 November 2010, Antalya.

16. Genc H, Dogru T, Kara M, et al. The risk of carotid atherosclerosis is not increased in non-alcoholic fatty liver disease without metabolic syndrome. P275. 27th National Gastroenterology Week 24-28 November 2010, Antalya.

17. Kara M, Dogru T, Genc H, et al. The role of hemoglobin in the relationship between non-alcoholic fatty liver disease and atherosclerosis. P 276. 27th National Gastroenterology Week 24-28 November 2010, Antalya.

18. Tasci I, Erdem G, Ozgur G, Genc H, et al. HMG-CoA reductase inhibitor treatment and platelet indices in patients with hypercholesterolemia. 5th National Metabolic Syndrome Symposium, Antalya, April 9-13, 2008, Obesity Reviews;9:276 (No:17).

19. Dogru T, Tasci I, Sonmez A, Genc H, et al. Soluble P-selectin levels in subjects with prediabetes. European J Clin Invest, 2nd Clinical Vascular Biology Congress, Antalya, vol. 36, 283, P50, Blackwell Publishing, 2006.

20. Dogru T, Sonmez A, Genc H, et al. The effect of fibrinogen and platelet aggregation on cardiovascular risk in prediabetic subjects. European J Clin Invest, 2nd Clinical Vascular Biology Congress, Antalya, vol. 36, 283, P49, Blackwell Publishing, 2006.

21. Tasci I, Dogru T, Sonmez A, Genc H, et al. Soluble CD40 ligand levels are not altered in subjects with impaired fasting glucose. European J Clin Invest, 2nd Clinical Vascular Biology Congress, Antalya, vol. 36, 272, P16, Blackwell Publishing, 2006

22. Ercin CN, Dogru T, Celebi G, Güler H, Genc H, et al. Blood Urea Nitrogen is not a marker for cardiovascular risk in early-stage non-alcoholic fatty liver disease patients. 31st National Gastroenterology Week, 25-30 November 2014.

23. Cintosun Ü, Dogru T, Genc H, et al. TWEAK; is it a new marker associated with fibrosis in non-alcoholic fatty liver disease? 31st National Gastroenterology Week, 25-30 November 2014.

24. Genc H, Dogru T, Celebi G, et al. High plasma pentraxin-3 levels are associated with endothelial dysfunction in non-alcoholic fatty liver disease. 31st National Gastroenterology Week, 25-30 November 2014.

25. Genc H, Dogru T, Tapan S, et al. Examination of the relationship between plasma vaspin levels and insulin resistance, adiponectin, and histological findings in non-alcoholic fatty liver disease. P078. 8th National Hepatology Congress, June 1-5, 2011, Ankara.

26. Genc H, Dogru T, et al. The risk of carotid atherosclerosis in non-alcoholic fatty liver disease: is it really high? P080 8th National Hepatology Congress, June 1-5, 2011, Ankara.

27. Erdem G, Genc H, Tasci I et al. Examination of plasma fibrinogen levels in individuals with impaired glucose tolerance, 44th National Diabetes Congress, PS37, Antalya, 2008.

28. Genc H, Tasci I, Erdem G, et al. Platelet indices in patients with impaired glucose tolerance, 44th National Diabetes Congress, PS46, Antalya, 2008.

29. Erdem G, Genc H, Tasci I et al.. Lipid profiles in patients with impaired glucose tolerance. 44th National Diabetes Congress, Antalya, PS44, 2008.

30. Genc H, Tapan S, Erdem G, et al.. Evaluation of white blood cell levels in patients with impaired glucose tolerance. 44th National Diabetes Congress, Antalya, PS29, 2008.

31. Karadurmuş, N., Doğru, T., Sönmez, A., Pınar, M., Genç, H et al. The use of aspirin in diabetic patients. 41st National Diabetes Congress, P26, Antalya, 2005.

32. Yılmaz, S., Karadurmuş, N., Sönmez, A., Doğru, T., Pınar, M., Genç, H., et al. Hypoglycemia and associated factors in diabetic cases. 41st National Diabetes Congress P58 Antalya, 2005

33. Genç, H., Sönmez, A., Doğru, T et al. The use of influenza and pneumococcal vaccines in diabetic patients. 41st National Diabetes Congress, P57, Antalya, 2005.

34. Genç, H., Doğru, T., Sönmez, A., et al. “Severe and symptomatic hypocalcemia due to oral risedronate therapy”, 6th National Internal Medicine Congress, P-066, Antalya, 2004.